Skip to Content

BETADINE DRY POWDER SPRAY

Active substance(s): POVIDONE-IODINE / POVIDONE-IODINE

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Betadine Dry Powder Spray.

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Povidone iodine 2.5 %w/w.
For excipients, see section 6.1

3

PHARMACEUTICAL FORM
Pressurised aerosol spray.

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Antiseptic for the treatment and prevention of infection in wounds including
ulcers, burns, cuts and other minor injuries.

4.2

Posology and method of administration
For topical use only.
Adults and children aged 2 years and older
Shake the can well before use. Spray the required area from a distance of 6-10
inches (15-25cm) until a dusting of powder is deposited. If necessary, the
treated area may be covered with a dressing.
Not to be used on children under 2 years of age.

4.3

Contraindications
Hypersensitivity to iodine, polyvinylpyrrolidine or to any excipient. History of
abnormal thyroid function or goitre (in particular nodular colloid goitre,
endemic goitre and Hashimoto’s thyroiditis). Use in children under two years

of age. Regular use should be avoided in patients on concurrent lithium
therapy. Avoid inhaling or spraying into the eyes.
Betadine Dry Powder Spray should not be used in serious cavities.

4.4

Special warnings and precautions for use
Use of this preparation may interfere with tests of thyroid function. Iodine is
absorbed through burns and broken skin and to a lesser extent through intact
skin and may lead to toxic levels of iodine in the blood, particularly in patients
with renal insufficiency. If symptoms occur suggesting changes in thyroid
function, these should be investigated. In patients with impaired renal
function, blood levels of iodine should be monitored.
If local irritation and hypersensitivity develop, then discontinue treatment.
Refer to section 4.8 for further information.
Betadine Dry Powder Spray can permanently discolour white gold jewellery
and it is recommended that this type of jewellery should be removed before
using Betadine Dry Powder Spray.

4.5

Interaction with other medicinal products and other forms of interaction
Use with concurrent lithium therapy has been shown to exhibit additive
hypothyroidic effects. Absorption of iodine from povidone iodine through
either intact skin or broken skin may interfere with thyroid function tests.
Contamination with povidone iodine of several types of tests for the detection
of occult blood in faeces or blood in urine may produce false-positive results.

4.6

Fertility, Pregnancy and lactation
Iodine freely crosses the placenta and is secreted in breast milk. Thyroid
function disorders have been reported in the offspring of mothers exposed to
pharmacological doses of iodine. Povidone iodine should not be used regularly
during pregnancy unless there is no alternative treatment available.

4.7

Effects on ability to drive and use machines
None.

4.8

Undesirable effects
Local irritation, skin burns and sensitivity reactions have been reported rarely.
Anaphylactic reactions, anaphylactoid reactions and anaphylactic shock have

been reported uncommonly with products containing povidone-iodine or
povidone.
Excess iodine can produce goitre and hypothyroidism or hyperthyroidism.
Such effects have occasionally been seen with extensive or prolonged use of
povidone iodine. Other effects that have been reported are metabolic acidosis
and acute renal failure.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk balance
of the medicinal product. Healthcare professionals are asked to report any
suspected adverse reactions via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard.

4.9

Overdose
Deliberate or accidental ingestion of large quantities of povidone iodine will
result in high blood concentrations of iodine and gastrointestinal corrosive
effects including vomiting, diarrhoea and abdominal pain. Systemic toxicity
may result in shock, hypotension, tachycardia, fever, metabolic acidosis and
renal impairment. Symptomatic and supportive treatment should be started
with special attention to monitoring electrolyte balance, renal function, thyroid
function and liver function. Haemodialysis effectively clears iodine and should
be employed in severe cases of iodine poisoning particularly if renal failure is
present. Continuous venovenous haemodiafiltration is less effective than
haemodialysis.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
ATC code: D08AG02 – Antiseptics and disinfectants

Povidone iodine is a complex of iodine, which retains the broad-spectrum
germicidal activity of the elemental iodine without its disadvantages. The
germicidal activity is maintained in the presence of blood, pus, serum and
necrotic tissue.

5.2

Pharmacokinetic properties
Not applicable.

5.3

Preclinical safety data
None stated.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Isopropyl myristate
N-pentane
Butane 40
Soya lecithin.

6.2

Incompatibilities
None known.

6.3

Shelf life
36 months unopened.

6.4

Special precautions for storage
Do not store above 25oC.

6.5

Nature and contents of container
Aerosol cans, containing 50, 100 or 150ml of product.
Not all pack sizes may be marketed.

6.6

Special precautions for disposal
None.

7

MARKETING AUTHORISATION HOLDER
Ayrton Saunders Ltd
9 Arkwright Road,
Astmoor Industrial Estate,
Runcorn,
Cheshire,
WA7 1NU,
UK

8

MARKETING AUTHORISATION NUMBER(S)
PL 16431/0190

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
19 April 2006

10

DATE OF REVISION OF THE TEXT
24/09/2015

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide